[Form 4/A] Barinthus Biotherapeutics plc. Amended Insider Trading Activity

Barinthus Biotherapeutics plc.

Rhea-AI Filing Summary

Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4/A filing submitted to the SEC.

Insider Trade Summary

Tender Offer: 8,797,770 shares

Tender Offer 1 txn

Insider Oxford Science Enterprises plc

Role Insider

Type	Security	Shares	Price	Value
Tender Offer	Ordinary Shares F1, F2	8,797,770	$0.111	$977K

Holdings After Transaction: Ordinary Shares — 0 shares (Direct)

Footnotes (2)

1. F1. Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.
2. F2. Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 11:01 AM Accepted by SEC EDGAR 09/11/2026 - 11:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oxford Science Enterprises plc

(Last) (First) (Middle)

46 WOODSTOCK ROAD

(Street)

OXFORD OX2 6HT

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Barinthus Biotherapeutics plc. [ BRNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			former 10% owner

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/06/2021

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	09/09/2026		U		8,797,770	D	$0.111(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share.

2. Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the "Issuer") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement.

Remarks:

In connection with the combination of Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc., Oxford Science Enterprises plc no longer beneficially owns more than 10% of the Issuer's Ordinary Shares, represented by American Depositary Shares. As a result, Oxford Science Enterprises plc is no longer subject to Section 16 of the U.S. Securities Exchange Act of 1934 with respect to the Issuer's Ordinary Shares and will no longer report transactions on Form 4 or Form 5.

	/S/Antonia Jenkinson	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)